Beyond immunotherapy-treatment advances in cell-based therapy for ovarian cancer and associated challenges.
作者信息
Cao Connie D, McCorkle J Robert, Kolesar Jill M
机构信息
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Kentucky Markey Comprehensive Cancer Center, Lexington, KY, USA.
Markey Comprehensive Cancer Center, University of Kentucky, Lexington, KY, USA.
出版信息
Gynecol Pelvic Med. 2024 Sep 30;7. doi: 10.21037/gpm-23-53. Epub 2024 Aug 17.
Abstract
摘要
相似文献
1
Beyond immunotherapy-treatment advances in cell-based therapy for ovarian cancer and associated challenges.卵巢癌基于细胞疗法的免疫治疗进展及相关挑战
Gynecol Pelvic Med. 2024 Sep 30;7. doi: 10.21037/gpm-23-53. Epub 2024 Aug 17.
2
Harnessing tumor immunogenomics: Tumor neoantigens in ovarian cancer and beyond.利用肿瘤免疫基因组学：卵巢癌及其他癌症中的肿瘤新抗原
Biochim Biophys Acta Rev Cancer. 2023 Nov;1878(6):189017. doi: 10.1016/j.bbcan.2023.189017. Epub 2023 Nov 5.
3
Circulating CD14 CD16 intermediate blood monocytes as a biomarker of ascites immune status and ovarian cancer progression.循环 CD14+CD16 中间型血单核细胞作为腹水免疫状态和卵巢癌进展的生物标志物。
J Immunother Cancer. 2020 Jun;8(1). doi: 10.1136/jitc-2019-000472.
4
Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy.上皮性卵巢癌与免疫系统：生物学、相互作用、挑战及免疫治疗的潜在进展
J Clin Med. 2020 Sep 14;9(9):2967. doi: 10.3390/jcm9092967.
5
Advances in nanotechnology-enabled drug delivery for combining PARP inhibitors and immunotherapy in advanced ovarian cancer.用于晚期卵巢癌中联合聚（ADP-核糖）聚合酶（PARP）抑制剂与免疫疗法的纳米技术驱动的药物递送进展。
Biomol Biomed. 2024 Mar 11;24(2):230-237. doi: 10.17305/bb.2023.9757.
6
Monocyte and interferon based therapy for the treatment of ovarian cancer.基于单核细胞和干扰素的卵巢癌治疗方法。
Cytokine Growth Factor Rev. 2016 Jun;29:109-15. doi: 10.1016/j.cytogfr.2016.02.006. Epub 2016 Mar 15.
7
Immunotherapy in ovarian cancer.卵巢癌的免疫疗法。
Curr Probl Cancer. 2017 Jan-Feb;41(1):48-63. doi: 10.1016/j.currproblcancer.2016.11.003. Epub 2016 Nov 15.
8
Platinum-based chemotherapy promotes antigen presenting potential in monocytes of patients with high-grade serous ovarian carcinoma.铂类化疗可提高高级别浆液性卵巢癌患者单核细胞的抗原呈递潜能。
Front Immunol. 2024 Sep 9;15:1414716. doi: 10.3389/fimmu.2024.1414716. eCollection 2024.
9
Immunotherapy in Recurrent Ovarian Cancer.复发性卵巢癌的免疫治疗
Biomedicines. 2025 Jan 12;13(1):168. doi: 10.3390/biomedicines13010168.
10
Immunotherapy for ovarian cancer.卵巢癌的免疫治疗。
Curr Treat Options Oncol. 2015 Jan;16(1):317. doi: 10.1007/s11864-014-0317-1.
本文引用的文献
1
Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial.阿替利珠单抗联合贝伐珠单抗和铂类化疗用于铂敏感复发性卵巢癌：安慰剂对照随机 III 期 ATALANTE/ENGOT-ov29 试验。
J Clin Oncol. 2023 Oct 20;41(30):4768-4778. doi: 10.1200/JCO.23.00529. Epub 2023 Aug 29.
2
Dual targeting ovarian cancer by Muc16 CAR T cells secreting a bispecific T cell engager antibody for an intracellular tumor antigen WT1.双靶点 CAR T 细胞治疗卵巢癌：MUC16 CAR T 细胞分泌双特异性 T 细胞衔接抗体，靶向细胞内肿瘤抗原 WT1
Cancer Immunol Immunother. 2023 Nov;72(11):3773-3786. doi: 10.1007/s00262-023-03529-w. Epub 2023 Aug 27.
3
Prevalence and prognostic role of PD-L1 in patients with gynecological cancers: A systematic review and meta-analysis.妇科恶性肿瘤患者 PD-L1 的流行状况及预后作用：系统评价和荟萃分析。
Crit Rev Oncol Hematol. 2023 Sep;189:104084. doi: 10.1016/j.critrevonc.2023.104084. Epub 2023 Aug 1.
4
Single CAR-T cell treatment controls disseminated ovarian cancer in a syngeneic mouse model.单次 CAR-T 细胞治疗可控制同种异体小鼠模型中的播散性卵巢癌。
J Immunother Cancer. 2023 May;11(5). doi: 10.1136/jitc-2022-006509.
5
TIL Therapy: Facts and Hopes.TIL 疗法：事实与展望。
Clin Cancer Res. 2023 Sep 1;29(17):3275-3283. doi: 10.1158/1078-0432.CCR-22-2428.
6
CAR-T Cells in the Treatment of Ovarian Cancer: A Promising Cell Therapy.嵌合抗原受体 T 细胞治疗卵巢癌：一种有前途的细胞疗法。
Biomolecules. 2023 Mar 2;13(3):465. doi: 10.3390/biom13030465.
7
Autologous T cell therapy for MAGE-A4 solid cancers in HLA-A*02 patients: a phase 1 trial.自体 T 细胞疗法治疗 HLA-A*02 患者的 MAGE-A4 实体瘤：一项 1 期临床试验。
Nat Med. 2023 Jan;29(1):104-114. doi: 10.1038/s41591-022-02128-z. Epub 2023 Jan 9.
8
Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial.腹腔内单核细胞加 IFNs 作为一种新型卵巢癌细胞免疫治疗方法：机制特征分析和 I 期临床试验结果。
Clin Cancer Res. 2023 Jan 17;29(2):349-363. doi: 10.1158/1078-0432.CCR-22-1893.
9
Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer.PD-1/PD-L1 阻断在复发性上皮性卵巢癌中的研究进展。
Front Immunol. 2022 Jun 27;13:901772. doi: 10.3389/fimmu.2022.901772. eCollection 2022.
10
Tumor-Associated Macrophages and Ovarian Cancer: Implications for Therapy.肿瘤相关巨噬细胞与卵巢癌：对治疗的启示
Cancers (Basel). 2022 Apr 29;14(9):2220. doi: 10.3390/cancers14092220.
Zotero 插件